Granules India has informed that the Board of Directors appointed Rajiv Pritidas Kakodkar (DIN: 01519590), as an Additional Director, categorized as Non-Executive Independent, on the Board of the Company with effect from February 20, 2024 and his appointment is subject to the approval of the members. The Board has approved this appointment by passing a resolution through the circulation. Pursuant to NSE Circular no. NSE/CML/2018/24 dated June 20, 2018, it has confirmed that Rajiv Pritidas Kakodkar is not debarred from holding the office of Director by virtue of any order of SEBI or any other authority. He meets the criteria for being appointed as an Independent Director under the statutes applicable to the Company. The details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, with respect to the above appointment, is given in the Annexure enclosed.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: